Yelak Biru | CureTalks
Yelak is an Information technology director for a fortune 50 global CPG company. He is also myeloma patient and advocate. Diagnosed with stage III myeloma at a young age of 25, Yelak was given 2-3 years to live. Two decades later, he continues to share the hope of living with myeloma by respecting the past, understanding the present and being energized by the future. Yelak is a member of the International Myeloma Foundation board of directors, a past speaker at EHA on Relapsed and Refractory myeloma, a facilitator at smartpatients.com, a member of the Global Myeloma Action network and an attendee of ASH since 2006. You can follow Yelak on twitter @NorthTxMSG
Related Talks
Melflufen for Myeloma: A Deep Dive
The FDA recently granted priority review to a new drug application for melflufen (INN melphalan flufenamide), in combination with dexamethasone. Melflufen is intended…
COVID 19 pandemic is here. What to expect?
COVID 19 is now a global pandemic.The cases of coronavirus are increasing rapidly across the world with the count crossing 246,005 globally and…
Treatments for Early Stage Plasma Cell Disorders
Plasma cell disorders like multiple myeloma, plasmacytoma, smoldering myeloma, MGUS are diseases in which the body makes too many plasma cells. These disorders…
Inherited Gene Mutations in Myeloma and Role of Precision Medicine
Multiple Myeloma is the second most common cancer of the blood and is largely incurable. A recent study has found that a specific…
Latest Advances in Myeloma Treatment: ASCO and EHA 2018 Highlights
The treatment field of Multiple Myeloma continues to move forward as novel agents and treatment combinations expand. Whether you are standard risk patient…